ViewRay Reports First Quarter 2021 Results
CLEVELAND, May 6, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2021.
First Quarter 2021 Highlights
- Received seven new orders for MRIdian systems totaling
$40.9 million , compared to four new orders totaling$22.6 million in the first quarter of 2020. - Total backlog increased to
$264.3 million as of March 31, 2021, compared to$230.8 million as of March 31, 2020. - Total revenue of
$15.5 million primarily from two revenue units, compared to$14.3 million primarily from three revenue units, including one system upgrade, in the first quarter of 2020. - Cash burn in the first quarter of 2021 was approximately
$28 million , excluding the net proceeds from the January 2021 public offering, compared to approximately$36 million in the first quarter of 2020. - Cash and cash equivalents were
$182.0 million as of March 31, 2021.
2021 Public Offering of Common Stock
- As previously disclosed, in January 2021, the Company raised aggregate net proceeds of approximately
$53.5 million after deducting the underwriting discounts, commissions, and estimated offering expenses via a public offering in which 11,856,500 shares of our common stock were issued and sold, including the full exercise of the underwriters' option to purchase additional shares, at a price to the public of$4.85 per share.
"Our performance in the first quarter 2021 represents a solid step forward and progress on our mission to improve the paradigm of care for cancer patients globally," said Scott Drake, President and CEO. "Our clinical and innovation pipelines are driving commercial traction. We look forward to upcoming clinical trial data and advancements in our product pipeline which we expect will fuel future growth."
Financial Results
Total revenue for the three months ended March 31, 2021 was
Total gross profit for the three months ended March 31, 2021 was
Total operating expenses for the three months ended March 31, 2021 were
Net loss for the three months ended March 31, 2021 was
ViewRay had total cash and cash equivalents of
Financial Guidance
Due to the ongoing impact and uncertainty of the COVID-19 pandemic globally, the Company will not be providing financial guidance at this time.
Conference Call and Webcast
ViewRay will hold a conference call to discuss results on Thursday, May 6, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (888) 771-4371 for domestic callers and (847) 585-4405 for international callers. The confirmation number is 50150605. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until May 13, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8484107.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay's expectations for 2021 and beyond and ViewRay's conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
VIEWRAY, INC. | ||||||||||
For the Three Months Ended March 31, | ||||||||||
2021 | 2020 | |||||||||
Revenue: | ||||||||||
Product | $ | 11,379 | $ | 11,470 | ||||||
Service | 4,027 | 2,661 | ||||||||
Distribution rights | 119 | 119 | ||||||||
Total revenue | 15,525 | 14,250 | ||||||||
Cost of revenue: | ||||||||||
Product | 10,685 | 13,129 | ||||||||
Service | 4,518 | 3,228 | ||||||||
Total cost of revenue | 15,203 | 16,357 | ||||||||
Gross profit (loss) | 322 | (2,107) | ||||||||
Operating expenses: | ||||||||||
Research and development | 6,510 | 6,337 | ||||||||
Selling and marketing | 2,848 | 5,823 | ||||||||
General and administrative | 15,639 | 15,788 | ||||||||
Total operating expenses | 24,997 | 27,948 | ||||||||
Loss from operations | (24,675) | (30,055) | ||||||||
Interest income | 2 | 695 | ||||||||
Interest expense | (1,058) | (1,038) | ||||||||
Other income (expense), net | (1,012) | 2,866 | ||||||||
Loss before provision for income taxes | $ | (26,743) | $ | (27,532) | ||||||
Provision for income taxes | — | — | ||||||||
Net loss and comprehensive loss | $ | (26,743) | $ | (27,532) | ||||||
Amortization of beneficial conversion feature related to Series A convertible preferred stock | — | — | ||||||||
Net loss attributable to common stockholders, basic and diluted | $ | (26,743) | $ | (27,532) | ||||||
Net loss per share, basic and diluted | $ | (0.17) | $ | (0.19) | ||||||
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted | 160,138,327 | 147,457,116 | ||||||||
Gross Orders | $ | 40,850 | $ | 22,600 | ||||||
Backlog | $ | 264,284 | $ | 230,792 | ||||||
VIEWRAY, INC. | ||||||||
March 31, 2021 | December 31, 2020 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 182,019 | $ | 156,720 | ||||
Accounts receivable | 16,569 | 11,769 | ||||||
Inventory, net of allowance of | 43,858 | 46,641 | ||||||
Deposits on purchased inventory | 2,550 | 2,084 | ||||||
Deferred cost of revenue | 2,310 | 1,954 | ||||||
Prepaid expenses and other current assets | 5,273 | 5,257 | ||||||
Total current assets | 252,579 | 224,425 | ||||||
Property and equipment, net | 22,822 | 24,062 | ||||||
Restricted cash | 1,460 | 1,460 | ||||||
Intangible assets, net | 48 | 50 | ||||||
Right-of-use assets | 9,553 | 10,129 | ||||||
Other assets | 1,428 | 1,426 | ||||||
TOTAL ASSETS | $ | 287,890 | $ | 261,552 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 7,591 | $ | 9,984 | ||||
Accrued liabilities | 14,164 | 19,281 | ||||||
Customer deposits | 15,433 | 15,463 | ||||||
Operating lease liability, current | 1,988 | 2,089 | ||||||
Current portion of long-term debt | — | — | ||||||
Deferred revenue, current | 10,022 | 10,094 | ||||||
Total current liabilities | 49,198 | 56,911 | ||||||
Deferred revenue, net of current portion | 2,089 | 2,572 | ||||||
Long-term debt | 57,022 | 56,940 | ||||||
Warrant liabilities | 5,484 | 4,864 | ||||||
Operating lease liability, noncurrent | 8,546 | 9,043 | ||||||
Other long-term liabilities | 1,146 | 956 | ||||||
TOTAL LIABILITIES | 123,485 | 131,286 | ||||||
Commitments and contingencies (Note 6) | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, par value of | — | — | ||||||
Common stock, par value of | 1,607 | 1,476 | ||||||
Additional paid-in capital | 816,625 | 755,874 | ||||||
Accumulated deficit | (653,827) | (627,084) | ||||||
TOTAL STOCKHOLDERS' EQUITY | 164,405 | 130,266 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 287,890 | $ | 261,552 | ||||
View original content:http://www.prnewswire.com/news-releases/viewray-reports-first-quarter-2021-results-301286013.html
SOURCE ViewRay, Inc.
